Apimeds Pharmaceuticals Us, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
AMEX
Inscobee Inc. and Apimeds Inc. file Amendment No. 4 to Schedule 13D, detailing a settlement agreement resolving disputes and granting an irrevocable proxy.
AMEX
Major holders led by Inscobee and Apimeds Inc. removed directors and executives at Apimeds Pharmaceuticals US via written consent, rejecting MindWave’s legal challenge.
AMEX
Majority shareholders of Apimeds Pharmaceuticals US, Inc. have removed the entire board and appointed new directors following concerns over a recent merger and digital asset ownership.
AMEX
SCHEDULE 13D/A: Apimeds Pharma Investors Challenge Merger, Allege Wrongdoing
Major shareholders of Apimeds Pharmaceuticals US, Inc. are challenging the validity of a recent merger with MindWave Innovations Inc., alleging potential wrongdoing by the board and management.
AMEX
SCHEDULE 13D: Inscobee and Apimeds Inc. Disclose Majority Stake in Apimeds Pharmaceuticals US Following IPO and Note Conversion
Inscobee Inc. and its subsidiary Apimeds Inc. have jointly disclosed a combined beneficial ownership of 55.4% in Apimeds Pharmaceuticals US, Inc. following the company's initial public offering and the conversion of outstanding promissory notes.